Gabelli Funds LLC Trims Stake in Globus Medical, Inc. $GMED

Gabelli Funds LLC lowered its holdings in Globus Medical, Inc. (NYSE:GMED) by 3.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 226,500 shares of the medical device company’s stock after selling 7,700 shares during the period. Gabelli Funds LLC’s holdings in Globus Medical were worth $19,776,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. William Blair Investment Management LLC raised its position in Globus Medical by 17.2% in the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after purchasing an additional 414,134 shares during the period. Sculptor Capital LP raised its position in Globus Medical by 31.9% in the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after purchasing an additional 667,850 shares during the period. Alliancebernstein L.P. raised its position in Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after purchasing an additional 1,908,795 shares during the period. Dimensional Fund Advisors LP raised its position in Globus Medical by 72.1% in the third quarter. Dimensional Fund Advisors LP now owns 2,011,104 shares of the medical device company’s stock valued at $115,166,000 after purchasing an additional 842,547 shares during the period. Finally, Marshall Wace LLP raised its position in Globus Medical by 8.3% in the third quarter. Marshall Wace LLP now owns 1,711,909 shares of the medical device company’s stock valued at $98,041,000 after purchasing an additional 131,433 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insider Activity

In related news, EVP Kelly Huller sold 20,000 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 18.38% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on GMED shares. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Royal Bank Of Canada boosted their price objective on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Truist Financial set a $115.00 price objective on Globus Medical in a report on Wednesday, February 25th. Finally, TD Cowen upgraded Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $106.36.

Globus Medical Trading Up 3.0%

GMED stock opened at $78.95 on Tuesday. The company has a market capitalization of $10.72 billion, a PE ratio of 18.36, a P/E/G ratio of 1.58 and a beta of 1.00. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The business’s fifty day moving average price is $87.57 and its 200 day moving average price is $87.36.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.